ERBB2 and neoplasm: These studies demonstrated the clinical potential of HER2 PET for detecting HER2-positive tumor lesions, evaluating HER2 heterogeneity, and identifying occult HER2-positive lesions in patients with HER2-negative breast cancer (7–12).